WILMINGTON — Clinical trials at Prelude Therapeutics have made significant headway with Phase 1 results of one of its drug candidates showing promising results. Interim data of clinical studies for a drug candidate known as PRT3789, a first-in-class, highly selective degrader of SMARCA2 protein was “well-tolerated” through eight doses levels – ranging between 24 milligrams […] The post 🔒 Prelude sees encouraging results in highly anticipated drug study appeared first on Delaware Business Times.